Aglietta, Massimo
University of Modena and Reggio Emilia · The University of Sydney · The University of Texas MD Anderson Cancer Center · Azienda Ospedaliero-Universitaria di Modena · Istituto Oncologico Veneto · University of Turin
6 papers on CoChatORCID 0000-0002-2255-7972
Most cited papers
- Verified
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Cited by 2,079
- Verified
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 568
- Verified
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation
Cited by 501
- Verified
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology
Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments
Cited by 359
- Verified
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 158
- Verified
BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody
Sanlorenzo, M., Vujic, I., Floris, A., Novelli, M., Gammaitoni, L., Giraudo, L., Macagno, M., Leuci, V., Rotolo, R., Donini, C., et al. (2018) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways
Cited by 47
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free